What is HC Wainwright’s Forecast for AUTL Q1 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Autolus Therapeutics in a report issued on Tuesday, February 17th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.28) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.11) EPS and FY2029 earnings at ($0.42) EPS.

AUTL has been the topic of several other research reports. Needham & Company LLC reduced their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Finally, Zacks Research downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.50.

Autolus Therapeutics Stock Up 3.3%

Shares of AUTL stock opened at $1.56 on Thursday. The firm has a market cap of $415.18 million, a price-to-earnings ratio of -1.88 and a beta of 1.98. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The stock has a 50-day moving average price of $1.57 and a 200 day moving average price of $1.57.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AUTL. Invesco Ltd. increased its position in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares in the last quarter. Jane Street Group LLC grew its stake in Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after acquiring an additional 91,222 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Autolus Therapeutics by 63.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock worth $69,000 after acquiring an additional 11,821 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Autolus Therapeutics during the second quarter worth about $50,000. Finally, Geode Capital Management LLC raised its position in shares of Autolus Therapeutics by 90.5% during the second quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock worth $375,000 after purchasing an additional 78,058 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong-Buy” and a $9.00 price target — a very large implied upside versus the current share price; this kind of initiation can attract momentum buyers and re-rate sentiment for a beaten-down biotech. Read More.
• Positive Sentiment: HC Wainwright published detailed EPS forecasts across FY2025–FY2030 and quarter-level EPS estimates (showing shrinking losses over time), reinforcing their view that Autolus’ pipeline and commercialization path could improve economics over the next several years — supportive for long-term bulls. Read More.
• Neutral Sentiment: Short-interest data for mid-February in the report appears to show zeros/NaN (likely a reporting anomaly) and therefore does not provide clear evidence of elevated short pressure driving the move.
• Negative Sentiment: Risks remain — the $9 target implies very large upside and may be optimistic given current cash burn, clinical/regulatory uncertainties and likely need for future financing; those factors could dilute shareholders or cause volatility if progress stalls.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.